Matthias Eyrich1, Susanne C Schreiber2, Johannes Rachor2, Jürgen Krauss3, Femke Pauwels4, Johannes Hain5, Matthias Wölfl2, Manfred B Lutz6, Steven de Vleeschouwer7, Paul G Schlegel2, Stefaan W Van Gool4. 1. Stem Cell Laboratory, University Children's Hospital Würzburg, University of Würzburg, Germany. Electronic address: eyrich_m@ukw.de. 2. Stem Cell Laboratory, University Children's Hospital Würzburg, University of Würzburg, Germany. 3. Department of Pediatric Neurosurgery, University Medical Center, Würzburg, Germany. 4. Laboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven, Belgium (on behalf of the HGG-Immuno Network). 5. Institute of Mathematics, University of Würzburg, Germany. 6. Institute of Virology and Immunobiology, University of Würzburg, Germany. 7. Laboratory of Experimental Neurosurgery and Neuroanatomy, Department of Neurosciences, KU Leuven, Belgium.
Abstract
BACKGROUND AND AIMS: One of the major challenges of dendritic cell (DC) vaccination is the establishment of harmonized DC production protocols. Here, we report the transfer and validation of a successfully used open DC manufacturing method into a closed system, good manufacturing practice (GMP)-compatible protocol. METHODS: All production steps (lysate generation, monocyte selection, DC culture and cryopreservation) were standardized and validated. RESULTS: Tumor lysate was characterized by histology, mechanically homogenized and avitalized. This preparation yielded a median of 58 ± 21 μg protein per milligram of tumor tissue. Avitality was determined by trypan blue staining and confirmed in an adenosine triphosphate release assay. Patient monocytes were isolated by elutriation or CD14 selection, which yielded equivalent results. DCs were subsequently differentiated in Teflon bags for an optimum of 7 days in CellGro medium supplemented with interleukin (IL)-4 and granulocyte macrophage colony stimulating factor and then matured for 48 h in tumor necrosis factor-α and IL-1ß after pulsing with tumor lysate. This protocol resulted in robust and reproducible upregulation of DC maturation markers such as cluster of differentiation (CD)80, CD83, CD86, human leukocyte antigen-DR and DC-SIGN. Functionality of these DCs was shown by directed migration toward C-C motif chemokine ligand 19/21, positive T-cell stimulatory capacity and the ability to prime antigen-specific T cells from naive CD8(+) T cells. Phenotype stability, vitality and functionality of DCs after cryopreservation, thawing and washing showed no significant loss of function. Comparison of clinical data from 146 patients having received vaccinations with plate-adherence versus GMP-grade DCs showed no inferiority of the latter. CONCLUSIONS: Our robust, validated and approved protocol for DC manufacturing forms the basis for a harmonized procedure to produce cancer vaccines, which paves the way for larger multi-center clinical trials.
BACKGROUND AND AIMS: One of the major challenges of dendritic cell (DC) vaccination is the establishment of harmonized DC production protocols. Here, we report the transfer and validation of a successfully used open DC manufacturing method into a closed system, good manufacturing practice (GMP)-compatible protocol. METHODS: All production steps (lysate generation, monocyte selection, DC culture and cryopreservation) were standardized and validated. RESULTS:Tumor lysate was characterized by histology, mechanically homogenized and avitalized. This preparation yielded a median of 58 ± 21 μg protein per milligram of tumor tissue. Avitality was determined by trypan blue staining and confirmed in an adenosine triphosphate release assay. Patient monocytes were isolated by elutriation or CD14 selection, which yielded equivalent results. DCs were subsequently differentiated in Teflon bags for an optimum of 7 days in CellGro medium supplemented with interleukin (IL)-4 and granulocyte macrophage colony stimulating factor and then matured for 48 h in tumor necrosis factor-α and IL-1ß after pulsing with tumor lysate. This protocol resulted in robust and reproducible upregulation of DC maturation markers such as cluster of differentiation (CD)80, CD83, CD86, human leukocyte antigen-DR and DC-SIGN. Functionality of these DCs was shown by directed migration toward C-C motif chemokine ligand 19/21, positive T-cell stimulatory capacity and the ability to prime antigen-specific T cells from naive CD8(+) T cells. Phenotype stability, vitality and functionality of DCs after cryopreservation, thawing and washing showed no significant loss of function. Comparison of clinical data from 146 patients having received vaccinations with plate-adherence versus GMP-grade DCs showed no inferiority of the latter. CONCLUSIONS: Our robust, validated and approved protocol for DC manufacturing forms the basis for a harmonized procedure to produce cancer vaccines, which paves the way for larger multi-center clinical trials.
Authors: S Borchers; C Maβlo; C A Müller; A Tahedl; J Volkind; Y Nowak; V Umansky; J Esterlechner; M H Frank; C Ganss; M A Kluth; J Utikal Journal: Clin Exp Immunol Date: 2017-10-24 Impact factor: 4.330
Authors: Philipp Gierlich; Veronika Lex; Antje Technau; Anne Keupp; Lorenz Morper; Amelie Glunz; Hanno Sennholz; Johannes Rachor; Sascha Sauer; Ana Marcu; Götz Ulrich Grigoleit; Matthias Wölfl; Paul G Schlegel; Matthias Eyrich Journal: Cancer Immunol Immunother Date: 2020-02-25 Impact factor: 6.968
Authors: Mario Löhr; Benjamin Freitag; Antje Technau; Jürgen Krauss; Camelia-Maria Monoranu; Johannes Rachor; Manfred B Lutz; Carsten Hagemann; Almuth F Kessler; Thomas Linsenmann; Matthias Wölfl; Ralf-Ingo Ernestus; Sabrina Engelhardt; Götz Gelbrich; Paul G Schlegel; Matthias Eyrich Journal: Cancer Immunol Immunother Date: 2018-07-27 Impact factor: 6.968
Authors: Alasdair R Fraser; Chloe Pass; Paul Burgoyne; Anne Atkinson; Laura Bailey; Audrey Laurie; Neil W A McGowan; Akib Hamid; Joanna K Moore; Benjamin J Dwyer; Marc L Turner; Stuart J Forbes; John D M Campbell Journal: Cytotherapy Date: 2017-06-30 Impact factor: 5.414